Singapore Exchange Ltd. · SGX:S68

Singapore Exchange — Biosensors International Group — 28th JPMorgan Healthcare Conference 2010

30 slides from Singapore Exchange's conference presentation, January 2010

  1. Slide 1: Biosensors International Group

    Biosensors International Group January 2010 JP Morgan Conference

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,”

  3. Slide 3: Overview of Biosensors

    Overview of Biosensors • Founded in 1990 – Public since 2005 (Singapore exchange b20.si) • Interventional cardiology and critical care product lines – interventional cardiology represents primary business • Global presence - USA, Switzerland, The Netherlands, China, India, Indonesia, Japan and Singa

  4. Slide 4: Transforming Biosensors' Technology into Shareholder Value

    Transforming Biosensors’ Technology into Shareholder Value Focused Strong 10% OUS Strengthen Restructure DES R&D Clinical DES Market Asia Operations Pipeline Data Share Position JP Morgan Conference

  5. Slide 5: Biosensors – Recent Changes and Restructuring

    Biosensors – Recent Changes and Restructuring • BioMatrix launched – April 2008; approvals obtained all over the world • Terumo contract restructured (excluding Japan) • US operations restructured – 60 employee reduction; facility consolidation • Netherlands manufacturing operation (Occam) closed –

  6. Slide 6: Boston Scientific (BSX) Statement – December 2008

    Boston Scientific (BSX) Statement – December 2008 “Finally, we acquired Labcoat Ltd. in Q4. Labcoat has developed a novel technology for coating drug-eluting stents that uses precisely metered droplets of a biodegradable polymer and drug formulation to create a thin coating confined to the outer sur

  7. Slide 7: WE ALREADY HAVE IT!!!!!

    Boston Scientific (BSX) Statement – December 2008 “Finally, we acquired Labcoat Ltd. in Q4. Labcoat has developed a novel technology for coating drug-eluting stents that uses precisely metered droplets of a biodegradable polymer and drug formulation to create a thin coating confined to the outer sur

  8. Slide 8: Biosensors' Drug-Eluting Stent Technology

    Biosensors’ Drug-Eluting Stent Technology • PLA carrier coating is co-released and degrades to CO2 + Water in ~ 6-9 months • Higher drug carrying capacity of PLA polymer results in 1/2 to 1/3 the amount of carrier polymer used vs. durable coatings • When the drug is gone, the carrier coating also go

  9. Slide 9: Proprietary BA9 Drug

    PROPRIETARY BA9™DRUG • A rapamycin derivative developed specifically for stent application by Biosensors • Effective immunosuppressive and anti-proliferative properties • Reduced systemic exposure and more localized drug effect due to highest lipophilic profile and abluminal coating LIPOPHILICITY CO

  10. Slide 10: Biosensors Drug-Eluting Stent R&D Pipeline

    Biosensors Durg-Eluting Stent R&D Pipeline Current DES Next Gen DES Long-term DCS & Platform Platform DES Platforms BioMatrix Flex BioFreedom • Biolimus A9 • LEADERS DES • Biolimus A9 • PLA Polymer • Biolimus A9 • No PLA polymer • Stainless Steel Stent • PLA Polymer • Surface treatments • Stainless

  11. Slide 11: BioFreedom Abluminal BA9-coated stent

    BioFreedom™ Abluminal BA9-coated stent • Special surface holds drug in abluminal surface structures • Potential advantages: • Avoid long term late adverse effects that might be attributable to the polymer • Improved surface integrity since there is no polymer to be sheared or pealed away from the st

  12. Slide 12: LEADERS All-Comers Trial

    LEADERS All-Comers Trial JP Morgan Conference Lancet 2008;327 (Sept 1)

  13. Slide 13: LEADERS: Clinical outcomes at 9 months

    LEADERS: Clinical outcomes at 9 months • LEADERS is the first head-to-head randomized study between the two drug-eluting stent systems (DES) in a ‘real world, all comers’ population using clinical results as its primary endpoint. Biolimus-eluting stent, Sirolimus-eluting stent, Odds ratio (95% Clini

  14. Slide 14: LEADERS Results at 24 Months

    LEADERS Results at 24 Months 2-year HR 0.84 [0.65 to 1.08] 20 1-year HR p = 0.18* BES 0.88 [0.66 to 1.17] SES p = 0.37* 15.4% -16% 15 12.1% Δ 2.4% -12% Δ 1.4% 13.0% % 10 10.7% 5 MACE = Cardiac Death, MI, or Clinically-Indicated TVR *P values for superiority 4 Klauss V., TCT 2009 0 0 3 6 9 12 15 18 2

  15. Slide 15: LEADERS: Summary clinical data at 24 months

    LEADERS: Summary clinical data at 24 months • BioMatrix performance continues to improve vs. Cypher • Potentially superior performance in higher risk patients • LST is very few specific cases – SVG patients • Potentially strong data regarding DAPT – potential long-term cost savings for patients Sour

  16. Slide 16: BioFreedom FIM Clinical Study

    BioFreedom FIM Clinical Study • Objectives – Determine that polymer-free drug-coated stent is as safe as the current generation DES products – Obtain enough data to design long-term study and product development program to position BioFreedom as the next generation of therapy – the “drug- coated ste

  17. Slide 17: BioFreedom Clinical Results Summary

    BioFreedom Clinical Results Summary • Equivalent safety and efficacy to Taxus with first 75 patient group • Significant reduction in late loss at 4 months compared to Taxus • IVUS results confirmed the angiographic findings • No stent thrombosis in any of the patients in the study through 4 months •

  18. Slide 18: Goal of 10% Market Share OUS for DES Products

    Goal of 10% Market Share OUS for DES Products • BioMatrix approved in most major geographies OUS • Recently approved in Korea; French approval anticipated before 31 March 2010 • China approval in process • Currently operating at 5% to 7% share in countries where BioMatrix is approved • Market share

  19. Slide 19: Europe and SE Asia Presence

    Europe and SE Asia Presence Western Europe 15 Direct Sales staff – UK,France,CH,Sweden 6 Biosensors Distributor Managers 17 Distributors with 95 staff. APAC 12 Direct Sales People HK,Taiwan,Singapore,Indonesia,Malaysia 10 Biosensors Sales team 11 Distributors with 65 staff. JP Morgan Conference

  20. Slide 20: ROW Infrastructure

    ROW Infrastructure Russia/CIS/EEU Japan 2 Biosensors Sales 23 Biosensors Sales / 14 Distributors with 62 customer service team staff. 1 Distributor with 50 staff. Canada 1 Biosensors Sales person 1 Distributors with 8 staff. LAM India/Pakistan/BD 3 Biosensors Sales team 10 Biosensors Staff 9 Distrib

  21. Slide 21: Record Product Revenues

    Record Product Revenues US$ MM $30.0 $25.0 $20.0 $15.0 $10.0 $5.0 $- FY09 Q1 FY09 Q2 FY09 Q3 FY09 Q4 FY10 Q1 FY10 Q2 DES IVP CCP JP Morgan Conference

  22. Slide 22: Drug-Eluting Stent Sales Growth

    Drug-Eluting Stent Sales Growth US$MM $12.5 $10.0 $7.5 $12.8m $11.1m $11.5m $10.7m $7.2m $8.2m $5.0 $2.5 $- FY09 Q1 FY09 Q2 FY09 Q3 FY09 Q4 FY10 Q1 FY10 Q2 JP Morgan Conference

  23. Slide 23: Measuring Change through Results

    Measuring Change through Results * Operating losses and cash flows adjusted for exchange gains or losses, Terumo US$40.0 million payment in Q1 FY 09 JP Morgan Conference

  24. Slide 24: Key markets in Asia Pacific (ex Japan) and projected DES revenue percentage contribution

    Key markets in Asia Pacific (ex Japan) and projected DES revenue percentage contribution Key markets and projected % contribution in Global Drug-Eluting Stent Market APAC (ex Japan) JP Morgan Conference

  25. Slide 25: China – 50% Ownership of JWMS

    China – 50% Ownership of JWMS • JWMS founded 2003 • Biosensors acquired 50% interest in JWMS in September 2007 (Shandong Weigao owns the other 50%) • 246 Employees - 186 manufacturing and operations; 60 sales representatives • Single product – Excel DES • Clinical study (CREATE) – over 2,000 patient

  26. Slide 26: JWMS Update

    JWMS Update • Weigao and Biosensors continue as JV partners • Biosensors and Weigao each consolidate 50% of JWMS profits • Biosensors continues to sell catheters to JWMS for Excel DES • Biosensors working actively to obtain regulatory approval for BioMatrix in China • Future relationship has many po

  27. Slide 27: JWMS – Summary Financial Data

    JWMS – Summary Financial Data JWMS Quarterly Revenues JWMS Annual Revenues $20.0 $50.0 $47.1 $16.0 $15.9 $14.4 $40.0 $15.0 $35.4 $12.2 $31.9 $10.7 $9.8 $11.1 $9.5 $30.0 $10.0 $23.3 $20.0 $5.0 $10.0 $- Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 $- 08 08 09 09 09 09 10 10 FY 2007 FY 2008 FY 2009 1H FY 2010 JWMS Quarterl

  28. Slide 28: Terumo Licensing Relationship

    Terumo Licensing Relationship • DES technology license – all elements; Nobori DES received CE mark approval in January 2009 • Territories outside USA and Japan – non-exclusive license expires in 2013 • Substantially all of the Company’s current license revenues are derived from non-exclusive Terumo

  29. Slide 29: Biosensors Key Assets and Value Components

    Biosensors Key Assets and Value Components • Leading DES technology position in Europe, Asia and Latin America markets - goal of 10% share in 3 years • 50% ownership position in one of the leading DES companies in China is a very undervalued asset • License arrangement with largest medical device ma

  30. Slide 30: Next for Biosensors

    Next for Biosensors • FYE 31 March 2011 plans and guidance • Capitalize on China business opportunity • Continued cost structure modification • R&D pipeline and clinical data progress • Terumo approval in Japan • Additional strategic relationships to accelerate growth opportunity JP Morgan Conferenc

Biosensors International Group — 28th JPMorgan Healthcare Conference 2010 on 6ix